tachycardia syndrome, POTS, is an autonomic condition resulting in a marked increase in heart rate ( 30 beats per minute) or a tachycardia ( 120 beats per minute), upon standing or tilt table testing without orthostatic hypotension. It is more frequent in females, (female: male ratio of 4.5:1), and most cases occur between ages of 15 and 25 years.
1
A current review of the literature demonstrates that the course of POTS in pregnancy is variable with similar proportions of patients reporting unchanged, worsened, and improved symptoms. [2] [3] [4] [5] For those patients who did report worsening symptoms, hyperemesis gravidarum, 2,6 migraine, 3 and presyncopal and syncopal episodes 4,7 were most common. The majority of studies have concluded that POTS does not appear to contribute to pregnancy-related complications 3, 4, 8 and show that vaginal delivery and regional anesthesia are generally safe in women with POTS.
Case Description Case 1
although with her prior pregnancy she did require β-blockade. The pregnancy had resulted in an uncomplicated delivery of a healthy and normally grown fetus at 38 weeks gestation. Although initially unremarkable without pharmacotherapy, she did experience disease exacerbation at approximately 15 weeks, which was not amenable to conservative measures. Propranolol (40 mg, twice daily) was started, which resulted in resolution of her symptoms. The remainder of the pregnancy was uncomplicated and resulted in a 40-week spontaneous labor and vaginal delivery of a healthy 3,638 g male infant with Apgar scores of 9 and 9. She did receive regional anesthesia (epidural) without complication. As of 6 weeks postpartum, she had an uneventful course and was doing well with on-going propranolol therapy (40 mg, twice daily).
Case 2
A 26-year-old Caucasian woman, gravida 1, para 0, was referred at 21 weeks to our Maternal-Fetal Medicine clinic for a pregnancy complicated by POTS (physical deconditioning type). Her medical history was significant only for the POTS, which was diagnosed 2 years earlier and managed by her Neurologist. She had previously been well managed with conservative measures, although exacerbation in the summer had required successful treatment with fludrocortisone. She had been started on propranolol (80 mg, once daily) by Neurology at 10 weeks due to exacerbation, which they had attributed to her underlying hyperemesis gravidarum. She continued propranolol (80 mg, once daily) throughout the pregnancy, which resulted in a 38-week spontaneous labor and vaginal delivery of a healthy 3,229 g female infant with Apgar scores of 8 and 9. She did receive regional anesthesia (epidural) without complication. As of 6 weeks postpartum, she had an uneventful course and was doing well with on-going propranolol therapy.
Discussion Presentation and Diagnosis
The diagnosis of POTS in pregnancy is difficult, as pregnancy itself may induce similar symptoms. 5 Diagnosis is made by careful history and the presence of a sustained heart rate increase by 30 beats per minute upon the transition from supine to standing position, improving in the recumbent position, for 6 months duration or longer. A standing heart rate of 120 beats per minute may also indicate POTS, but this may not be an appropriate criterion for those with a low resting rate. A standing norepinephrine level 600 pg/mL (seen in 30-60% of POTS patients 1 ) and other clinically indicated laboratory, cardiac, and neurologic evaluations can be used to confirm diagnosis. 1, 4 However, other causes of orthostatic symptoms should be ruled out before extensive cardiac or neurologic testing is performed, and may include thyroid dysfunction, pregnancy, anemia, diabetes, and more. 
Classification
There are several subtypes of POTS, including neuropathic, hyperadrenergic, and POTS-related to volume dysregulation and physical deconditioning. Knowing a patient's POTS subtype is important in directing management of this condition in pregnancy and delivery. 9 Neuropathic POTS describes patients who demonstrate a loss of peripheral sympathetic innervation to the lower limbs resulting in venous pooling. Hyperadrenergic POTS is caused by excessive sympathetic drive and is marked by a standing plasma norepinephrine 600 pg/mL, and fluctuating and/or increased blood pressure during head-up tilt. In patients with hyperadrenergic POTS, episodes may be triggered by emotional and physical stimuli. Patients with the volume dysregulation variant of POTS have low plasma, red cell, and total blood volumes. This could be related to low plasma renin and aldosterone activity, high plasma angiotensin II levels indicating reduced ACE-2 activity, and gastrointestinal disorders resulting in poor fluid intake and/or retention. Physical deconditioning is another form of POTS, and is revealed by significant and persistent tachycardia during exercise or when upright, as well as reduced stroke volume and a relatively low peak oxygen uptake compared with control groups. This could be caused by an inefficient baroreceptor reflex and vestibulosympathetic reflex due to bed rest or deconditioning.
1
Antepartum Considerations
The course of POTS in pregnancy is variable. [2] [3] [4] [5] In general, patients who did not require treatment before pregnancy were less likely to report exacerbation during pregnancy.
4
One retrospective case study performed by Khalil et al, evaluating outcomes of 22 pregnant women with preexisting POTS, reported the worsening of symptoms occurred solely in the first trimester, and the authors attributed symptom resolution thereafter to increased fluid retention during the second and third trimesters. 3 However, a case review by Glatter et al of two other patients with severe POTS reported a worsening of symptoms at 6 months gestation, and hyperemesis gravidarum. 6 Kimpinski et al compared POTS in parous and nulliparous women looking at POTS in 116 pregnancies and found no notable difference in the course of the condition between pregnant women, and women who were not pregnant. 8 Peggs et al conducted a similar study of 29 pregnant women with POTS and found no difference in symptoms of faintness before and during pregnancy.
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The majority of studies have concluded that POTS does not appear to contribute to pregnancy-related complications.
3,4,8,10 A retrospective study by Blitshteyn et al, examining 10 women with a total of 17 live births reported a higher miscarriage rate in this study cohort (41%, excluding a strong outlier), which is higher than the rate of the general population (31%). 2 This finding was contrary to that of other studies of women with preexisting POTS.
3-6,8
Intrapartum Considerations
Many women with POTS have been able to undergo safe vaginal delivery, [3] [4] [5] 7, 11 even without anesthesia. 4 The presence of POTS should generally not influence the choice of whether to deliver vaginally or by cesarean section. In some cases it may be important to establish analgesia early in labor to prevent a tachycardic response. 7, 9 It has been shown that nonpregnant patients with POTS experience a relatively larger decrease in blood pressure in the early phases of Valsalva, accompanied by a subsequently large increase in blood pressure and heart rate in the later phases. McEvoy et al, who examined the anesthetic management of POTS in delivery, suggested that in the pregnant patient these hemodynamic changes could increase pelvic blood vessel resistance thereby decreasing uteroplacental blood flow. They therefore concluded that it is safest to monitor hemodynamics frequently especially in the second phase of labor and consider avoiding Valsalva by opting for instrumental or cesarean delivery if hemodynamic variations do not return to normal between contractions. 9 It must be cautioned that this is the only study to suggest an alteration in the mode of delivery.
Therapy
Management of POTS includes volume expansion, physical counter maneuvers, pharmacotherapy, and behavioralcognitive therapy. Most patients require volume expansion with adequate intake of water and sodium. Caffeine intake should be limited as it may promote hypovolemia by increasing diuresis. Physical counter maneuvers may be helpful by producing small increases in mean arterial pressure and include making a fist, bending forward, and placing a foot on a chair. Compression stockings may also be helpful.
1
Pharmacologic treatments include mineralocorticoids such as fludrocortisone, α-1 agonists such as midodrine, β blockers such as propanolol, and cholinesterase inhibitors such as pyridostigmine.
1 Below is a brief overview of pregnancy and lactation consideration for the four more commonly employed pharmacotherapies for POTS:
1. Fludrocortisone: There are no pregnancy or lactation studies on fludrocortisone specifically; however, the data with respect to glucocorticoid use in pregnancy suggest an increased risk for cleft palate and possible impaired fetal growth and an otherwise relatively safe profile. 12 The
American Academy of Pediatrics classifies glucocorticoids as compatible with breastfeeding. 2. Midodrine: Pregnancy data with midodrine is limited to the case report by Glatter et al, 6 which included a normal infant. There are otherwise no human data on pregnancy or lactation with respect to this agent. In general, due to its vasoconstrictive properties, it should be used with caution due to theoretically increased risk for fetal vascular insults (e.g., gastroschisis). 
3.
Propranolol: Pregnancy data with respect to propranolol have not indicated an increased risk for teratogenicity; however, an association with neonatal apnea, respiratory distress, bradycardia, and hypoglycemia has been suggested. 15 The American Academy of Pediatrics classifies it as compatible with breastfeeding. 4. Pyridostigmine: Pregnancy data have not indicated an increased risk for teratogenicity or adverse perinatal outcomes. 16 The World Health Organization and American Academy of Pediatrics classify pyridostigmine as compatible with breastfeeding.
13,17
5. Phenylephrine is commonly used to treat hypotension associated with neuraxial blockade in POTS patients.
7,9
Although a vasoconstricting agent (similar to midodrine), teratogenicity, and lactation are not a major concern, as this agent is generally used intrapartum and in a short exposure window.
In conclusion and based on our cases and review of the literature, POTS does not appear to confer an increased risk of adverse perinatal outcomes. While the first trimester may confer increased risk of disease exacerbation, the fluid retention in second and third trimester should prove beneficial. Management should start with identification of the subtype of POTS, and include conservative measures before initiation of pharmacotherapy. Propranolol should be the first considered agent due to its safe pregnancy and lactation profile. Timing and mode of delivery should be reserved for usual obstetrical indications.
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